Comparative Pharmacology
Head-to-head clinical analysis: ELIPHOS versus FAMOTIDINE CALCIUM CARBONATE AND MAGNESIUM HYDROXIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ELIPHOS versus FAMOTIDINE CALCIUM CARBONATE AND MAGNESIUM HYDROXIDE.
ELIPHOS vs FAMOTIDINE, CALCIUM CARBONATE, AND MAGNESIUM HYDROXIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
ELIPHOS is a phosphate binder that works by binding dietary phosphate in the gastrointestinal tract, forming non-absorbable complexes that are excreted in the feces, thereby reducing serum phosphate levels.
Famotidine is a competitive histamine H2-receptor antagonist that inhibits gastric acid secretion by blocking H2 receptors on parietal cells. Calcium carbonate and magnesium hydroxide act as antacids, neutralizing gastric acid via chemical neutralization.
10 mg orally once daily, with or without food.
1 tablet (famotidine 10 mg, calcium carbonate 800 mg, magnesium hydroxide 165 mg) orally once or twice daily as needed for heartburn; maximum 2 tablets in 24 hours.
None Documented
None Documented
Terminal elimination half-life is 3-5 hours in patients with normal renal function; prolonged in renal impairment.
Famotidine: 2.5-3.5 hours (prolonged in renal impairment, up to 20 hours when CrCl <10 mL/min).
Renal excretion of unchanged drug accounts for 60-70% of elimination; biliary/fecal excretion accounts for 20-30%; approximately 10% is metabolized.
Famotidine: renal (65-70% unchanged), biliary/fecal (30-35%). Calcium carbonate: feces (unabsorbed calcium), urine (absorbed). Magnesium hydroxide: feces (unabsorbed magnesium), urine (absorbed).
Category C
Category A/B
Antacid
Antacid / Laxative